Live Breaking News & Updates on Innovator Pharmaceutical

Stay updated with breaking news from Innovator pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Eu

EQS-News: Marinomed Biotech AG / Key word(s): ContractMarinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe 26.03.2024 / 07:45 CET/CESTThe issuer is solely responsible for the content of this announcement.Marinomed Biotech AG enters new Carragelose distribution part. ....

United Arab Emirates , United States , Lucia Ziegler , Vitaplus Kft , Ceres Pharma , Eva Ruppnig , Andreas Grassauer , Metrum Communications , International Media Contact , Procter Gamble , Vienna Stock Exchange , Ceres Pharma Group , Marinomed Biotech , Eastern Europe , Eastern European , Belgium Based Ceres , Gulf Region , Asian Pharmaceutical , Innovator Pharmaceutical , North America ,

EQS-News: Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe

EQS-News: Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

United States , United Arab Emirates , Andreas Grassauer , Eva Ruppnig , Vitaplus Kft , Lucia Ziegler , Ceres Pharma , Vienna Stock Exchange , Procter Gamble , International Media Contact , Metrum Communications , Ceres Pharma Group , Marinomed Biotech , Eastern Europe , Eastern European , Belgium Based Ceres , Gulf Region , Asian Pharmaceutical , Innovator Pharmaceutical , North America ,

Hikal hits the roof after 10-year multi product deal


Hikal hit an upper circuit of 10% at Rs 313.65 after the company said it signed a 10-year multi product deal with a leading global pharmaceutical innovator company.The contract entails the development and supply of a portfolio of niche APIs over a period of 10 years. The development will start this year and commercial supplies will commence post successful development and plant commercialisation estimated to be in FY 2024 onwards. With this deal, Hikal is entering into a niche area of chemistry and products thereby bolstering its animal health vertical. Hikal and its customer will be jointly investing at its Panoli, Gujarat site to setup a multipurpose manufacturing asset for manufacturing of these APIs. ....

Sameer Hiremath , Capital Market , Pharmaceutical Industry , Harmaceuticals Nec , Manufacturing Facility , Ultipurpose Manufacturing Asset , Chemicals Industry , Innovator Pharmaceutical , Chief Executive Officer Ceo , Ustainable Long Term Competitive , மூலதனம் சந்தை , மருந்து தொழில் ,